Skip to main navigation Skip to search Skip to main content

Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity

  • Ying Jing
  • , Yuan Liu
  • , Qiang Li
  • , Youqiong Ye
  • , Lixia Diao
  • , Yun Huang
  • , Yubin Zhou
  • , Michael R. Green
  • , Gordon B. Mills
  • , Leng Han

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)1558-1559
Number of pages2
JournalCancer Cell
Volume39
Issue number12
DOIs
StatePublished - Dec 13 2021

Funding

This work was supported by the Cancer Prevention & Research Institute of Texas ( RR150085 and RP190570 to L.H.), NIH ( U01 CA217842 to G.B.M), and The Welch Foundation ( BE-1913-20190330 to Y.Z.). M.R.G is a Scholar of the Leukemia and Lymphoma Society. We thank LeeAnn Chastain for editorial assistance. Detailed methods and list of CAR targets are available at https://hanlab.tamhsc.edu/CARTSC/#!/download , and all other associated data are available within the data portal. This work was supported by the Cancer Prevention & Research Institute of Texas (RR150085 and RP190570 to L.H.), NIH (U01 CA217842 to G.B.M), and The Welch Foundation (BE-1913-20190330 to Y.Z.). M.R.G is a Scholar of the Leukemia and Lymphoma Society. We thank LeeAnn Chastain for editorial assistance. Detailed methods and list of CAR targets are available at https://hanlab.tamhsc.edu/CARTSC/#!/download, and all other associated data are available within the data portal. M.R.G. has stock ownership interest in KDAc Therapeutics; receives funding from Kite/Gilead, Allogene, Sanofi, and Abbvie; and has received an honorarium from Tessa Therapeutics. G.B.M notes personal fees for consulting from Abbvie, Amphista, AstraZeneca, Chrysallis Biotechnology, GSK, ELlipses Pharma, ImmunoMET, Ionis, Lilly, Medacorp, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Turbine, and Zentalis Pharmaceuticals; stock options from Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, and Turbine; and has licensed technology of homologous recombination deficiency (HRD) assay to Myriad Genetics and digital saptial profiler (DSP ) patents with Nanostring. All other authors declare no competing interests.

FundersFunder number
Gilead/Kite
Myriad Genetics and digital saptial profiler
Signalchem Lifesciences
Tessa Therapeutics and Kuur Therapeutics
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health
National Institute of Health-National Cancer InstituteU01CA217842
Welch FoundationBE-1913-20190330
Cancer Prevention and Research Institute of TexasRP190570, RR150085
Leukemia and Lymphoma Society
AbbVie

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this